Pierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the Europe Economic Area, UK, and Switzerland. Urovant Sciences GmbH ...
Myrbetriq (mirabegron) is a brand-name drug that’s prescribed for overactive bladder in adults and certain children. It’s an extended-release medication. As with other drugs, Myrbetriq can cause side ...
Constipation may increase your risk of developing urinary tract infections (UTIs) by putting pressure on your bladder. This pressure may lead to urinary retention and bacterial growth. Share on ...
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)-- Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ...
The approval was based on data from the pivotal phase 3 EMPOWUR study. The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron; Urovant Sciences) for the treatment of overactive ...
Axonics Modulation Technologies has received premarket approval from the Food and Drug Administration (FDA) for Axonics r-SNM System, an implantable sacral neuromodulation device (SMN), for the ...
A number of female patients, aged 60 and older, have been found to have urinary retention during the recovery period following total hip replacement or hip fracture. (Whether the retention preceded or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback